Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.5K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

852
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
852
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

1.0K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.0K
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

522
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
522

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

High-Frequency Spinal Cord Stimulation Modifies Tibial Nerve-Stimulation-Evoked Cortical Theta-Gamma Coupling in Sheep Cortex.

The European journal of neuroscience·2026
Same journal

Sex Differences in Behavioral Responses to Chronic Unpredictable Mild Stress in Swiss Mice.

The European journal of neuroscience·2026
Same journal

Neural Correlates of Emotional Memory Biases in Adult Attachment: An Event-Related Potential Study.

The European journal of neuroscience·2026
Same journal

Anterior Superior Longitudinal Fasciculus Microstructure Correlates With Bimanual Visuomotor Performance in Healthy Younger but Not Older Adults.

The European journal of neuroscience·2026
Same journal

The Role of Genetic Alterations in the Emergence of Alzheimer's Disease in Down Syndrome: A Review.

The European journal of neuroscience·2026
Same journal

The Diverse Role of ipRGCs in Visual Perception Beyond Non-Image-Forming Functions.

The European journal of neuroscience·2026

Related Experiment Video

Updated: Dec 21, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.2K

Shedding light on dyskinesias.

Ivan Castela1,2, Ledia F Hernandez1,2

  • 1HM-CINAC, Hospital Universitario HM Puerta del Sur, Fundación de Investigación HM Hospitales, Madrid, Spain.

The European Journal of Neuroscience
|May 13, 2020
PubMed
Summary

Levodopa treatment for Parkinson disease can cause dyskinesia due to striatal pathway imbalance. Targeting these pathways may offer new cell-type therapies to re-balance brain activity and reduce motor symptoms.

Keywords:
OptodyskinesiasParkinson diseasedopaminelevodopa-induced dyskinesiasstriatum

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.3K
Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
05:52

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

Published on: November 21, 2013

15.3K

Related Experiment Videos

Last Updated: Dec 21, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.2K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.3K
Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
05:52

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

Published on: November 21, 2013

15.3K

Area of Science:

  • Neuroscience
  • Neurology
  • Pharmacology

Background:

  • Levodopa (L-DOPA) is a primary Parkinson disease treatment, but prolonged use leads to levodopa-induced dyskinesias (LIDs).
  • Alterations in the striatal efferent circuitry, particularly the direct and indirect pathways, are implicated in LIDs.
  • The precise role of the indirect pathway in dyskinesia pathophysiology is still under investigation.

Purpose of the Study:

  • To review current understanding of striatal pathway involvement in LIDs.
  • To explore how dopamine depletion and dyskinetic conditions alter striatal pathway activity.
  • To identify potential cell-type specific therapeutic targets for re-balancing striatal activity.

Main Methods:

  • Review of recent and past research findings on LIDs and striatal circuitry.
  • Analysis of optogenetic and chemogenetic studies in animal models.
  • Examination of evidence from both animal models and human Parkinson disease patients.

Main Results:

  • Both striatal direct and indirect pathways show altered activity in dopamine depletion and dyskinesia.
  • Structural and functional changes in indirect pathway neurons contribute to dyskinesia.
  • Striatal pathway imbalance can induce dyskinetic behaviors, even without dopamine denervation.

Conclusions:

  • A critical imbalance between striatal pathways is sufficient to cause dyskinesia.
  • Understanding these pathway dynamics is crucial for developing targeted therapies.
  • Future research should focus on cell-type specific interventions to restore striatal pathway balance.